Author

D. W. Felsher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

I. Lai· 2 shared J. Park· 2 shared A. Gill· 1 shared A. S. Hansen· 1 shared A. Suresh· 1 shared G. L. Burnett· 1 shared J. A. M. Smith· 1 shared J. W. Evans· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

I. Lai

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MYC Overexpression Drives Immune Evasion in Human Cancer that is Reversible Through Restoration of Pro-Inflammatory Macrophages

R. Dhanasekaran, A. S. Hansen, J. Park, I. Lai, N. Adeniji, S. Kuruvilla, A. Suresh, V. Swamy, D. W. Felsher

This paper shows that MYC overexpression in cancers suppresses immune surveillance by inhibiting pro-inflammatory macrophages, and this immune evasion can be reversed by combined PDL1 and CTLA4 blockade.

bioRxiv · May 13, 2022 · PreprintCancer Biology

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy

W. D. Mahauad-Fernandez, Y. C. Yang, I. Lai, J. Park, L. Yao, J. W. Evans, G. L. Burnett, A. Gill, J. A. M. Smith, M. Singh, D. W. Felsher

This study identifies bi-steric mTORC1-selective inhibitors that reactivate 4EBP1, suppress MYC-driven tumors, and enhance immunotherapy in multiple cancer models.

bioRxiv · Feb 4, 2022 · PreprintCancer Biology